Key Highlights

  • Revenue was USD 2.22 million against an estimate of USD 2.71 million.
  • Net loss per share was USD 2.44 against an estimate of a USD 2.60 loss.
  • Clinic Revenue was USD 2.21 million, compared with USD 1.72 million.
  • Cash was USD 3.70 million at September 30, 2026.

INVO Fertility (NASDAQ:IVF) reported total revenue of USD 2.22 million for the third quarter of 2026, compared with USD 1.76 million in the prior-year quarter, against an estimate of USD 2.71 million. Basic and diluted net loss per common share was USD 2.44, compared with USD 157.43, against an estimate of a USD 2.60 loss.

Clinic revenue was USD 2.21 million, compared with USD 1.72 million, and product revenue was USD 15,069, compared with USD 34,871.

Third Quarter Results

Cost of services was USD 1.44 million, compared with USD 1.12 million. Selling, general and administrative expenses were USD 2.07 million, compared with USD 2.13 million, and Depreciation and amortization was USD 177,564, compared with USD 136,741. Total operating expenses were USD 3.70 million, compared with USD 3.39 million.

The loss from operations was USD 1.48 million, compared with USD 1.64 million. The change in Fair Value of Derivatives was a loss of USD 562,997, interest income was USD 74,735 and interest expense was USD 154,768, compared with USD 322,765. Total other expense was USD 643,030, compared with USD 1.76 million.

Net Loss and Nine-Month Results

The net loss from continuing operations was USD 2.15 million, compared with USD 3.40 million, and the provision for income taxes was USD 29,530. For the nine months, total revenue was USD 6.41 million, compared with USD 5.26 million, and net loss per common share was USD 11.20, compared with USD 722.84 for continuing operations in the prior-year period.

Per share amounts reflect the number of shares outstanding in each period as presented in the filing.

Balance Sheet and Going Concern Disclosure

Cash was USD 3.70 million at September 30, 2026, compared with USD 2.08 million at December 31, 2025. Total Assets were USD 25.50 million, compared with USD 20.22 million, and Goodwill was USD 9.24 million. The Balance Sheet includes an Investment in NAYA Therapeutics of USD 2.47 million and a note receivable from NAYA Therapeutics of USD 5.24 million.

Total liabilities were USD 7.49 million, compared with USD 13.00 million. Total current liabilities were USD 4.46 million, compared with USD 10.33 million. The filing states that there is substantial doubt about the company's ability to continue as a going concern for at least one year from the date the financial statements were issued, and that the company would need to raise additional capital.

The filing reports a loss on Debt extinguishment of USD 172,621 for the nine months and a gain on remeasurement of USD 2.45 million, alongside a loss of USD 4.35 million on the change in fair value of derivatives for the period. Selling, general and administrative expenses for the nine months were USD 6.15 million, compared with USD 5.88 million, and the loss from operations was USD 4.36 million, compared with USD 5.83 million.

INVO Fertility Q3 2026 Earnings: Key Takeaways

INVO Fertility reported third quarter 2026 total revenue of USD 2.22 million and a net loss per share of USD 2.44. Cash was USD 3.70 million and total liabilities were USD 7.49 million at September 30, 2026.